Novavax, Inc (NVAX) concluded trading on Wednesday at a closing price of $6.76, with 5.45 million shares of worth about $36.83 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -18.36% during that period and on July 02, 2025 the price saw a gain of about 2.27%. Currently the company’s common shares owned by public are about 161.96M shares, out of which, 147.54M shares are available for trading.
Stock saw a price change of 4.32% in past 5 days and over the past one month there was a price change of -4.38%. Year-to-date (YTD), NVAX shares are showing a performance of -46.60% which decreased to -15.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.01 but also hit the highest price of $17.81 during that period. The average intraday trading volume for Novavax, Inc shares is 9.01 million. The stock is currently trading -0.17% below its 20-day simple moving average (SMA20), while that difference is down -0.05% for SMA50 and it goes to -20.04% lower than SMA200.
Novavax, Inc (NASDAQ: NVAX) currently have 161.96M outstanding shares and institutions hold larger chunk of about 56.79% of that.
The stock has a current market capitalization of $1.09B and its 3Y-monthly beta is at 2.49. PE ratio of stock for trailing 12 months is 2.55, while it has posted earnings per share of $2.65 in the same period. It has Quick Ratio of 2.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 5.40% while standing at 5.14% over the month.
Stock’s fiscal year EPS is expected to rise by 298.25% while it is estimated to decrease by -90.69% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on June 17, 2025 offering a Sell rating for the stock and assigned a target price of $6 to it. Coverage by BTIG Research stated Novavax, Inc (NVAX) stock as a Buy in their note to investors on February 28, 2025, suggesting a price target of $19 for the stock. Stock get a Neutral rating from BofA Securities on May 10, 2024.
